Indications:

Adults with type 2 diabetes.

Usage Dosage:

It is a basal insulin that can be administered by subcutaneous injection once daily at any time of the day, preferably at the same time each day.

Insulin analogs, including degu insulin, have potencies expressed in units (U). One (1) unit (U) of degu insulin is equivalent to one (1) international unit (IU) of human insulin, one (1) unit of glucagon, or one (1) unit of diethylstilbestrol.

In patients with type 2 diabetes mellitus, this product may be used alone or in combination with oral antidiabetic medications and mealtime insulin.

The dose of this product will depend on the needs of the individual patient. Dose adjustments based on fasting blood glucose are recommended to optimize glycemic control. As with all other insulin medicines, dose adjustments may be required if the patient's physical activity increases, their daily diet changes or concomitant illnesses occur.

Dosing Flexibility:

This product provides flexibility in the timing of insulin administration if situations are encountered where it is not possible to administer the drug at the same time each day. However, it should be ensured that at least 8 hours elapse between two adjacent injections.

It is recommended that patients who forget to administer the medication be given it immediately upon discovery and thereafter continue the regular once-daily dosing regimen.

Starting Dose:

Patients who have not used insulin:

The recommended starting daily dose is 10 units, followed by individualized dose adjustments.

Patients with prior insulin use:

For patients with type 2 diabetes mellitus treated with basal insulin, basal-mealtime insulin, premixed insulin, or self-mixed insulin, convert the portion of prior basal insulin to this product at an equivalent dose, followed by individualized dose adjustments.

Close monitoring of blood glucose is recommended during conversion to this product and in subsequent weeks. Dosage and timing of administration of co-administered rapid-acting or short-acting insulin medications or other concomitant antidiabetic therapeutic agents may need to be adjusted.

Method of Administration:

This product is intended for subcutaneous use only.

This product should not be administered intravenously; intravenous administration may cause severe hypoglycemia.

This product should not be administered intramuscularly; intramuscular administration may alter drug absorption.

This product must not be used in an insulin infusion pump.

This product may be injected subcutaneously in the thigh, upper arm or abdominal wall. Injection sites should always be rotated in the same area to minimize the risk of impaired fat metabolism.

The information is from the Internet and is for reference only.